Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Frizzled2-Fc (Fz2-Fc) is a recombinant fusion protein consisting of the extracellular domain of the Frizzled-2 receptor fused to an Fc domain. It acts as a soluble decoy receptor or protein "trap" designed to bind Wnt ligands and inhibit Wnt signaling. Although designed to reduce Wnt signaling, preclinical studies in mouse models of osteogenesis imperfecta (OI) have shown that Frizzled2-Fc paradoxically increases bone mass, cortical thickness, and bone strength, potentially through activation of the Wnt/mTORC1 pathway. It is being investigated by researchers at Baylor College of Medicine and the University of Texas Health Science Center at Houston as a potential anabolic therapy for the treatment of osteogenesis imperfecta.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Frizzled2-Fc.